Taking your statements one by one... "The goals for this scam is to (sic)": "Print stock" Note as of the latest supplemental filed at otcmarkets.com, no stock has been issued since 3 million shares on 4/4/16 and the listed share count as of 5/11/17 was 387.86 million, unchanged since that time period. Shares were purchased and issued before then, at prices .003 and significantly above. Prices and recipients are all listed per OTC requirements. The facts say "print stock" statement is FALSE.
"Send out misleading press releases" Here is verifiable information regarding the press releases you falsely cited as "lies" Lets briefly cover the 4 press releases cited:
1. The most relevant regarding sales in Mexico states that sales under distributor Merck SA de CV had expanded. While true, sales were still inhibited by lack of follow through from the turnover of 5 managers in 4 years at Merck and the diversion of funds by Schlosser and Squires from fulfillment of orders that harmed the company severely. The company almost didn't make it through the that escapade and went dark for about 2 years and now works with distributor MDR in Mexico and has Sucanon on shelves and online at Similares Farmacias throughout Mexico. So while there have been many ups and downs in the history of ROTH/FROI and BIOHF before that, sales have significantly increased since the time of that announcement.
2. Regarding the 2011 press releases about distribution in the Middle East, the same Schlosser/Squires debacle that brought operations to a near halt everywhere including Mexico also affected this area, with Iran specifically (the subject of the other press release) facing additional hurdles due to Iran sanctions by the UN. Specifically the agreement with Bahestan Darou (http://www.behestandarou.com/) Iran was nullified by President Obama when he slapped trading embargo on Iran. Any who follow the company link will see they are real and work with Pfizer, Bausch and Lomb, Merck, etc.
3. The China press release was generated as the referenced company Tianjin contacted the company unsolicited about distributing Sucanon in China. They were going to pursue all the regulatory approvals required and the PR issued to disclose material information. As background, diab2 was studied in China and approved for sale there in 1997 when Rieveley ran BIOHF. I think the distributor was Volque pharmaceuticals at that time but the focus turned to Latin America with subsequent study and approval in Mexico and Peru. By the way, the name of the Mexico subsidiary at the time BIOHF first operated there was Pharmaroth, just to additionally clear up the name issue that is frequently referenced "no one named ROTH." Anyhow, the Chinese company Tianjin did not follow through as they were bought out by another Chinese company that focuses on generic drugs in India, so there is currently no activity in China nor does that company have any rights under the agreement. That does not in any of these cases equate to a phony press release at the time.
4. Just to head off the next obvious argument before it is raised, by contrast, Canagen is actively working through the Indian government approval process and is invested in the effort. Stockholders are awaiting word on the progress of approval in India and the results from the completed clinical trial in Mexico City.
Nonwithstanding the fact that the press releases cited are several years old, the facts above again say that the "lying press release" accusation is FALSE.
"Irving a notorious associate of Manion, Handy and all the notorious scams they ran" From your posted information about Irving, he worked for the company Manion ran, 20 years ago give or take and Manion apparently went to prison. It's called "guilt by association" and a more subtle tactic to falsely drag someone through the mud rather than the attic of falsely calling Irvings associate Clark a convicted felon. These things appear to be done because Irving was never charged. Mostly FALSE on these as well...
"Changed names many times" FALSE as name changed once from FROI to ROTH when Squires and Schlosser were removed for taking money out of the company that was supposed to fulfill Sucanon orders in Mexico with distributor Merck. That almost put the company under but for CEO Lopez deferring his salary and keeping things afloat. Now let's ask, why would the CEO defer his salary unless he believes strongly in the product? According to your flawed logic he could have taken a salary all along by printing more shares (which has been disproven) and not risk losing his pay if the company failed.
Since there are so many false statements, the others will be addressed separately...
News 
Market Data 
Discover 
